Diagonal Bio
Detects genetic materials in real time with high accuracy and sensitivity using a simple, one-step assay.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor | €0.0 | round |
| N/A | €0.0 | round | |
* | SEK500k | Post IPO Equity | |
| Total Funding | 000k | ||
Related Content
Diagonal Bio is at the forefront of developing diagnostic technologies aimed at enhancing the identification of genetic markers, particularly in the context of disease management. The company operates within the medtech sector, leveraging a unique combination of molecular biology and electrochemistry to accelerate the accurate detection of genetic markers. This approach is particularly relevant in the wake of the COVID-19 pandemic, where rapid and precise diagnostics are crucial. Diagonal Bio's patented technology, LAMPlify, is designed to serve both regulated and less regulated market segments, providing versatile applications in genetic identification. The company primarily targets healthcare providers and research institutions that require advanced diagnostic solutions. Diagonal Bio's business model likely involves the development and licensing of its proprietary technologies, generating revenue through partnerships and sales to medical and research entities. The company is based in Sweden and is actively expanding its team to support its growth and innovation efforts.
Keywords: diagnostic, genetic markers, molecular biology, electrochemistry, disease management, medtech, LAMPlify, healthcare, Sweden, innovation.